Secondary histiocytic sarcoma with BRAF V600E mutation after T‐cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib

2020 ◽  
Vol 67 (5) ◽  
Author(s):  
Vinayak Venkataraman ◽  
Lucas R. Massoth ◽  
Ryan J. Sullivan ◽  
Alison M. Friedmann
Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3470-3470
Author(s):  
D. Maroeska W.M. te Loo ◽  
Esmé Waanders ◽  
Patricia JTA Groenen ◽  
Annet Simons ◽  
Jacques J.M. van Dongen ◽  
...  

Abstract Abstract 3470 Hematopoiesis is traditionally seen as the unidirectional maturation of stem cells into lineage committed cells. Recent data are suggestive for some degree of lineage flexibility in both normal as malignant cells. We here present a boy that presented with T-cell acute lymphoblastic leukemia (T-ALL). During T-ALL treatment, the patient developed in short time a non-Langerhans-cell histiocytose in the ileum, and subsequently a disseminated form of histiocytic sarcoma (a.o. also in the liver). Interestingly, the same clonal T cell receptor (TCR) gene rearrangements were found in all three malignancies (TCRB-VJ, TCRG-VJ and TCRB-DJ) indicating they were related. There were no immunoglobulin rearrangements. To understand the evolution from T-ALL to non-Langerhans-cell histiocytose and to histiocytic sarcoma, an extensive genetic analysis was performed. Using a SNP6.0 array platform we analyzed DNA isolated from T-ALL cells, a bone marrow sample obtained during complete remission from theT-ALL, a biopsy from the ileum tumor, the liver tumor, and DNA isolated from skin fibroblasts. The three tumor samples were not fully concordant in the SNP analysis, with lesions acquired but also absent from subsequent samples. All three tumor samples showed identical TCR gene rearrangements as well as a loss of the CDKN2A/B region, the only gene-containing copy number aberration (CNA) present in the T-ALL. The T-ALL sample showed a homozygous loss of the CDKN2A/B region, whereas both the ileum and liver samples showed a heterozygous loss. In addition, the three tumor samples shared two 1Mb regions of loss of heterozygosity (LOH) on chromosomes 6p and 11p, containing DDB2, MADD and RUNX2, amongst others. A gain on chromosome 19q containing 12 genes was shared between the ileum and liver sample only. In addition, the ileum tumor showed 14 non-shared CNAs of which 11 losses, 2 homozygous losses, and 1 gain, affecting 11 genes including ZFAT, PTPRK and beta-catenin (CTNNB1). The liver tumor acquired gains of a large part of chromosome 5, the p-arm of chromosome 11 and the q-arm of chromosome 22 reminiscent of a chromothrypsis event. The PAX5 gene indicated in the progression of an ALL to histiocytic sarcoma was not affected in either of the samples. These results indicate that the three tumors are related but did not evolve from each other in a linear manner. Apparently, the common oncogenetic transformation occurred at an early differentiation stage with lineage plasticity, i.e. with some lineage specification but without full lineage commitment. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Kehan Li ◽  
Cunte Chen ◽  
Rili Gao ◽  
Xibao Yu ◽  
Youxue Huang ◽  
...  

AbstractT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of leukemia with poor prognosis, and biomarkers and novel therapeutic targets are urgently needed for this disease. Our previous studies have found that inhibition of the B-cell leukemia/lymphoma 11B (BCL11B) gene could significantly promote the apoptosis and growth retardation of T-ALL cells, but the molecular mechanism underlying this effect remains unclear. This study intends to investigate genes downstream of BCL11B and further explore its function in T-ALL cells. We found that PTK7 was a potential downstream target of BCL11B in T-ALL. Compared with the healthy individuals (HIs), PTK7 was overexpressed in T-ALL cells, and BCL11B expression was positively correlated with PTK7 expression. Importantly, BCL11B knockdown reduced PTK7 expression in T-ALL cells. Similar to the effects of BCL11B silencing, downregulation of PTK7 inhibited cell proliferation and induced apoptosis in Molt-4 cells via up-regulating the expression of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and p27. Altogether, our studies suggest that PTK7 is a potential downstream target of BCL11B, and downregulation of PTK7 expression via inhibition of the BCL11B pathway induces growth retardation and apoptosis in T-ALL cells.


2015 ◽  
Vol 208 (1-2) ◽  
pp. 52-53 ◽  
Author(s):  
Xiaolin Ma ◽  
Lijun Wen ◽  
Lili Wu ◽  
Qingrong Wang ◽  
Hong Yao ◽  
...  

2021 ◽  
Vol 22 (3) ◽  
pp. 1388
Author(s):  
Natalia Maćkowska ◽  
Monika Drobna-Śledzińska ◽  
Michał Witt ◽  
Małgorzata Dawidowska

Distinct DNA methylation signatures, related to different prognosis, have been observed across many cancers, including T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological neoplasm. By global methylation analysis, two major phenotypes might be observed in T-ALL: hypermethylation related to better outcome and hypomethylation, which is a candidate marker of poor prognosis. Moreover, DNA methylation holds more than a clinical meaning. It reflects the replicative history of leukemic cells and most likely different mechanisms underlying leukemia development in these T-ALL subtypes. The elucidation of the mechanisms and aberrations specific to (epi-)genomic subtypes might pave the way towards predictive diagnostics and precision medicine in T-ALL. We present the current state of knowledge on the role of DNA methylation in T-ALL. We describe the involvement of DNA methylation in normal hematopoiesis and T-cell development, focusing on epigenetic aberrations contributing to this leukemia. We further review the research investigating distinct methylation phenotypes in T-ALL, related to different outcomes, pointing to the most recent research aimed to unravel the biological mechanisms behind differential methylation. We highlight how technological advancements facilitated broadening the perspective of the investigation into DNA methylation and how this has changed our understanding of the roles of this epigenetic modification in T-ALL.


Sign in / Sign up

Export Citation Format

Share Document